FDA Approved: PIOGLITAZONE AND GLIMEPIRIDE — Supplemental Application (Prasco Laboratories)

View source ↗

Summary

FDA supplemental application approval for a fixed-dose combination of pioglitazone and glimepiride, filed by Prasco Laboratories.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Glimepiride (glimepiride)
• PIOGLITAZONE (Pioglitazone)

Snippet

SUPPL AP for PIOGLITAZONE AND GLIMEPIRIDE (PIOGLITAZONE AND GLIMEPIRIDE)